Search

Your search keyword '"Hanna, Kaijankoski"' showing total 2 results
Start Over Author "Hanna, Kaijankoski" Publication Year Range Last 3 years
2 results on '"Hanna, Kaijankoski"'

1. Neuropathic Pain Medication and Antidepressant Use after Disability Pension in Patients with Spinal Cord Stimulation for Persistent Spinal Pain Syndrome

Author

Hanna Kaijankoski, Mette Nissen, Tiina-Mari Ikäheimo, Mikael von und zu Fraunberg, Olavi Airaksinen, and Jukka Huttunen

Subjects
Medicine (General), R5-920
Abstract

Background. Treatment of persistent spinal pain syndrome (PSPS) is challenging. Chronic pain associated with PSPS can lead to an impaired ability to work. Objective. To obtain information on whether receiving a disability pension (DP) affects pain and pain treatments in retiring working-age PSPS patients. Neuropathic pain medication and antidepressant use were considered as an indicator of neuropathic pain. Methods. The study group comprised 129 consecutive PSPS patients with spinal cord stimulation (SCS) devices implanted at Kuopio University Hospital Neurosurgery between January 1, 1996, and December 31, 2014. Purchase data of gabapentinoids, tricyclic antidepressants, and serotonin-norepinephrine reuptake inhibitors from January 1995 to March 2016, as well as the data on working ability, were retrieved from national registries. Results. The data showed that 28 of 129 (21.7%) SCS permanent patients had a DP, and 27 had a sufficient follow-up time (two years before and one year after DP). Most patients (61%) used neuropathic pain medications during the follow-up, while 44% used antidepressants. Most patients (70%, n = 19) retired because of dorsopathies. The dose of gabapentinoids started to increase before the DP; after the DP, the doses started to increase again after the decrease but remained at a lower level. Conclusions. Neuropathic pain medication and antidepressant use suggest that pain continues after the DP—that is, pensioners continue to experience inconvenient chronic pain. Resources for patient care are therefore needed after the DP. However, the DP reduces the dose increase of gabapentinoids; the dose is higher immediately before retirement than at the end of the follow-up.

Published
2024
Full Text
View/download PDF

2. Disability Pension Did Not Reduce Opioid Use Among Patients With Failed Back Surgery Syndrome Who Were Trialed and Implanted for Spinal Cord Stimulation

Author

Hanna, Kaijankoski, Mette, Nissen, Janne, Pesonen, Tiina-Mari, Ikaheimo, Mikael, von Und Zu Fraunberg, Olavi, Airaksinen, and Jukka, Huttunen

Subjects
Analgesics, Opioid, Pensions, Spinal Cord Stimulation, Treatment Outcome, Spinal Cord, Humans, Chronic Pain, Failed Back Surgery Syndrome, Opioid-Related Disorders, Retrospective Studies
Abstract

Spinal cord stimulation (SCS) is an effective treatment for failed back surgery syndrome (FBSS). In patients with FBSS, opioids have often been initiated, even before SCS is trialed.We studied the effect of retirement on opioid use in patients with chronic pain after failed back surgery.A retrospective study design.The study was conducted at Kuopio University Hospital.The study group consisted of all 230 patients with SCS trialed or implanted for FBSS at Kuopio University Hospital Neurosurgery from January 1, 1996 through December 31, 2014. All purchases of prescribed opioids and their daily defined doses, as well as data on working ability, were obtained from the Social Insurance Institution. Patients were divided into 3 groups: SCS trial only, SCS implanted permanently, and SCS implanted but later explanted. We analyzed the differences in opioid use among these groups 2 years before and 2 years after the start of their disability pension (DP).During the follow-up period, a total of 60 patients received a DP. One year before DP, the majority of patients used opioids (n = 43, 72%), and throughout the one-year follow-up after retirement, the number of users increased slightly (n = 46, 77%). In the permanently implanted SCS group, the number of strong opioid users decreased after retirement. Most patients used a moderate dose (0.1-10.5 morphine milligram equivalent/d). Retirement appeared to interrupt dose escalation in all groups, but doses increased further as the follow-up continued.No structured questionnaires were used in this study. Also, many underlying factors contributing to chronic pain were missing.DP did not reduce the use of opioids in patients with FBSS. Opioid doses were lower and dose escalation less steep with continuous SCS therapy.

Published
2022

Catalog

Books, media, physical & digital resources
See catalog results